Completed PHASE2 INTERVENTIONAL NCT00248248

DOXIL for Consolidation Therapy in Ovarian Cancer.

A Phase II Non-randomized Study of DOXIL Consolidation Treatment for Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneal Carcinoma.

Sponsor: Ortho Biotech, Inc.

Conditions Ovarian Neoplasm

Interventions liposomal doxorubicin

Updated 5 times since 2017 Last updated: Oct 7, 2011 Started: Oct 31, 2005 Primary completion: Oct 31, 2011 Completion: Oct 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Ovarian Neoplasm, this trial is completed. The trial is conducted by Ortho Biotech, Inc. and has accumulated 5 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ortho Biotech, Inc.
Southeastern Gynecologic Oncology

Data source: Southeastern Gynecologic Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Atlanta, United States